医学
疾病
胆固醇
家族性高胆固醇血症
他汀类
药理学
HMG-CoA还原酶
还原酶
重症监护医学
生物信息学
内科学
酶
生物
生物化学
作者
Andrea Mormone,Giovanni Tortorella,Francesca Esposito,Alfredo Caturano,Aldo Marrone,Domenico Cozzolino,Raffaele Galiero,Raffaele Marfella,Ferdinando Carlo Sasso,Luca Rinaldi
出处
期刊:Biomedicines
[Multidisciplinary Digital Publishing Institute]
日期:2024-02-14
卷期号:12 (2): 432-432
被引量:2
标识
DOI:10.3390/biomedicines12020432
摘要
Hypercholesterolemia plays a crucial role in the formation of lipid plaques, particularly with elevated low-density lipoprotein (LDL-C) levels, which are linked to increased risks of cardiovascular disease, cerebrovascular disease, and peripheral arterial disease. Controlling blood cholesterol values, specifically reducing LDL-C, is widely recognized as a key modifiable risk factor for decreasing the morbidity and mortality associated with cardiovascular diseases. Historically, statins, by inhibiting the enzyme β-hydroxy β-methylglutaryl-coenzyme A (HMG)-CoA reductase, have been among the most effective drugs. However, newer non-statin agents have since been introduced into hypercholesterolemia therapy, providing a viable alternative with a favorable cost–benefit ratio. This paper aims to delve into the latest therapies, shedding light on their mechanisms of action and therapeutic benefits.
科研通智能强力驱动
Strongly Powered by AbleSci AI